These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 11386264)

  • 1. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.
    ; Eichhorn EJ; Domanski MJ; Krause-Steinrauf H; Bristow MR; Lavori PW
    N Engl J Med; 2001 May; 344(22):1659-67. PubMed ID: 11386264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of benefit and early hazard of bucindolol for Class IV heart failure.
    Anderson JL; Krause-Steinrauf H; Goldman S; Clemson BS; Domanski MJ; Hager WD; Murray DR; Mann DL; Massie BM; McNamara DM; Oren R; Rogers WJ;
    J Card Fail; 2003 Aug; 9(4):266-77. PubMed ID: 13680547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of carvedilol on survival in severe chronic heart failure.
    Packer M; Coats AJ; Fowler MB; Katus HA; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Roecker EB; Schultz MK; DeMets DL;
    N Engl J Med; 2001 May; 344(22):1651-8. PubMed ID: 11386263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
    Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH
    N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial.
    Domanski M; Krause-Steinrauf H; Deedwania P; Follmann D; Ghali JK; Gilbert E; Haffner S; Katz R; Lindenfeld J; Lowes BD; Martin W; McGrew F; Bristow MR;
    J Am Coll Cardiol; 2003 Sep; 42(5):914-22. PubMed ID: 12957443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy.
    O'Connor CM; Gottlieb S; Bourque JM; Krause-Steinrauf H; Anand I; Anderson JL; Plehn JF; Silver MA; White M; Carson P;
    Am J Cardiol; 2005 Mar; 95(5):558-64. PubMed ID: 15721091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
    Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN; Tognoni G;
    N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST).
    Frantz RP; Lowes BD; Grayburn PA; White M; Krause-Steinrauf H; Krishnan V; Uyeda L; Burnett JC;
    J Card Fail; 2007 Aug; 13(6):437-44. PubMed ID: 17675057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
    Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S;
    Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.
    Kao DP; Davis G; Aleong R; O'Connor CM; Fiuzat M; Carson PE; Anand IS; Plehn JF; Gottlieb SS; Silver MA; Lindenfeld J; Miller AB; White M; Murphy GA; Sauer W; Bristow MR
    Eur J Heart Fail; 2013 Mar; 15(3):324-33. PubMed ID: 23223178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incomplete bucindolol evaluation in acute myocardial infarction Trial (BEAT).
    Torp-Pedersen C; Køber L; Ball S; Hall A; Brendorp B; Ottesen M; Berning J; Jensen G; Hampton J; Zilles P; Eberle S; Carlsen J
    Eur J Heart Fail; 2002 Aug; 4(4):495-9. PubMed ID: 12167390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo.
    Gilbert EM; Anderson JL; Deitchman D; Yanowitz FG; O'Connell JB; Renlund DG; Bartholomew M; Mealey PC; Larrabee P; Bristow MR
    Am J Med; 1990 Mar; 88(3):223-9. PubMed ID: 1968710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure.
    Aleong RG; Sauer WH; Robertson AD; Liggett SB; Bristow MR
    Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):137-43. PubMed ID: 23275278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet; 1999 Jan; 353(9146):9-13. PubMed ID: 10023943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bucindolol, systolic blood pressure, and outcomes in systolic heart failure: a prespecified post hoc analysis of BEST.
    White M; Desai RV; Guichard JL; Mujib M; Aban IB; Ahmed MI; Feller MA; de Denus S; Ahmed A
    Can J Cardiol; 2012 May; 28(3):354-9. PubMed ID: 21982425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators.
    Bristow MR; O'Connell JB; Gilbert EM; French WJ; Leatherman G; Kantrowitz NE; Orie J; Smucker ML; Marshall G; Kelly P
    Circulation; 1994 Apr; 89(4):1632-42. PubMed ID: 7908610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial.
    Bristow MR; Krause-Steinrauf H; Nuzzo R; Liang CS; Lindenfeld J; Lowes BD; Hattler B; Abraham WT; Olson L; Krueger S; Thaneemit-Chen S; Hare JM; Loeb HS; Domanski MJ; Eichhorn EJ; Zelis R; Lavori P
    Circulation; 2004 Sep; 110(11):1437-42. PubMed ID: 15337700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.
    Hjalmarson A; Goldstein S; Fagerberg B; Wedel H; Waagstein F; Kjekshus J; Wikstrand J; El Allaf D; Vítovec J; Aldershvile J; Halinen M; Dietz R; Neuhaus KL; Jánosi A; Thorgeirsson G; Dunselman PH; Gullestad L; Kuch J; Herlitz J; Rickenbacher P; Ball S; Gottlieb S; Deedwania P
    JAMA; 2000 Mar; 283(10):1295-302. PubMed ID: 10714728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
    Torp-Pedersen C; Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Hanrath P; Komajda M; Lutiger B; Metra M; Remme WJ; Scherhag A; Skene A;
    Am Heart J; 2005 Feb; 149(2):370-6. PubMed ID: 15846279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.